Balance Sheet
Includes Current Assets, Liabilities and Stockholder's Equity
Quarter Ended Jun 30, 2020
As of June 30, 2020, Adaptimmune had cash and cash equivalents of $122.4 million and Total Liquidity of $419.0 million.
Revenue for the three and six months ended June 30, 2020 was $0.5 million.
For Fiscal Year Ending Dec 31, 2019
For complete information regarding our financials, see our periodic filings